Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Craddock, Charles; Slade, Daniel; De Santo, Carmela; Wheat, Rachel; Ferguson, Paul; Hodgkinson, Andrea; Brock, Kristian; Cavenagh, Jamie; Ingram, Wendy; Dennis, Mike; Malladi, Ram; Siddique, Shamyla; Mussai, Francis; Yap, Christina

doi:10.1200/jco.18.00889

Public

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Published in Journal of Clinical Oncology • Jan 17, 2019

Authors:

Charles Craddock

Daniel Slade

Carmela De Santo

Abstract

PURPOSE: Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and azacitidine (AZA) possess significant antitumor a...

Subject

Medicine

Azacitidine

Transplantation

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!